The online version of this article (doi:10.1007/s40120-014-0019-4) contains supplementary material, which is available to authorized users.
Current treatments for relapsing–remitting multiple sclerosis (RRMS) are only partially effective. The objective of this study was to characterize treatment response in RRMS patients in Portugal to 12-month therapy with first-line disease-modifying therapies.
In this retrospective study, neurologists at participating centers completed survey questionnaires using records of patients with RRMS who had received first-line treatment with one of five European Medicine Agency-approved agents in the 12 months prior to inclusion in the survey. Sub-optimal responders included patients treated for at least 1 year, and who had ≥1 relapse(s) or an increase of 1.5 points on the Expanded Disability Status Scale (EDSS; if baseline EDSS was 0) or an increase of ≥0.5 points (baseline EDSS ≥1). Optimal responders included patients treated for at least 1 year without relapse and who had an increase of <1.5 points on EDSS (if baseline EDSS was 0) or no increase in EDSS (baseline EDSS ≥1).
Data for 1,131 patients from 15 centers were analyzed. Twenty-six percent (95% confidence interval 23–28%) of patients had sub-optimal treatment response. Duration of therapy (P < 0.001), age at the start of therapy (P = 0.03), and baseline EDSS score (P < 0.001), were significantly different among treatments. Sub-optimal treatment response appeared to be related only to a more severe EDSS score at baseline and did not differ among therapies.
Neurologists should closely monitor patients to optimize treatment strategies and better control disease, improving prognosis.
Sa MJ, Guimaraes J, Abreu P, Mendes A, Souto BE. Etiopathogenesis, classical immunotherapy and innovative nanotherapeutics for inflammatory neurological disorders. Curr Nanosci. 2011;7:2–20. CrossRef
Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993;43:655–61.
Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. [Erratum appears in Lancet 1999;353(9153):678]. Lancet 1998;352:1498–504.
Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). [Erratum appears in Ann Neurol 1996;40(3):480]. Ann Neurol 1996;39:285–94.
Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45:1268–76. PubMedCrossRef
Rudick RA. Measuring the impact of therapeutic intervention. Neurology. 2010;74:S1–2. CrossRef
Entidade Reguladora da Saúde (2007) Avaliação do acesso dos doentes com EM a consultas externas nos Hospitais do SNS. Available https://www.ers.pt/uploads/writer_file/document/101/824937_rel.pdf. Last accessed Aug 6, 2014.
Carra A, Onaha P, Sinay V, et al. A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing–remitting multiple sclerosis. Eur J Neurol Off J Eur Fed Neurol Soc. 2003;10:671–6.
- Relapsing–Remitting Multiple Sclerosis: Patterns of Response to Disease-Modifying Therapies and Associated Factors: A National Survey
Maria José Sá
João de Sá
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II